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Introduction. Since the 20th century tobacco smoking has had an enormous impact on morbidity and mortality in 
the adult population, and it remains the greatest single preventable health risk factor worldwide. Cancer is the se-
cond leading cause of death in Poland, with lung cancer as the primary cause of cancer-related death in Polish men 
and women. Given these statistics, this manuscript aims to estimate tobacco-attributable cancer mortality in Poland.
Material and methods. Data on cancer mortality come from the WHO Mortality Statistics database. Data on smoking 
prevalence in Poland come from standardized surveys based on nationally representative samples. Data on relative 
risks come from the Cancer Prevention Study II. Tobacco-attributable fractions were calculated using standard me-
thodology for calculating population-based attributable fractions.
Results. In 2014, there were over 24 thousand tobacco-attributed cancer deaths in men. Lung cancer tops the list of 
ranked cancer types, with a tobacco-attributable fraction of 93%. Next is laryngeal (TAF = 90%), oropharyngeal (TAF 
= 86%) and esophageal (TAF = 80%) cancer. Overall, two-thirds of the considered cancer deaths were attributed to 
tobacco smoke (TAF = 75%). In 2014, there were over 7.5 thousand of cancer deaths related to smoking in women. 
Here, both laryngeal and lung cancer (both TAF = 76%) top the ranked list. Next are esophageal (TAF = 61%) and 
oropharyngeal (TAF = 51%) cancers, and when combined almost half of all considered cancer deaths were attributed 
to tobacco smoke (TAF = 44%). 
Conclusions. Tobacco smoking and tobacco-attributable cancer mortality remain one of the greatest health burdens 
in Poles. Each year over 30 thousand Polish men and women die of cancer caused by smoking. All these deaths could 
be avoided.
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Introduction
Since the 20th century tobacco smoking has enormo-
usly impacted population morbidity and mortality, and it 
remains the largest single preventable health-related risk 
factor worldwide. Historically cancer mortality was linked 
to carcinogen exposure in tobacco smoke. In developed 
countries cancer mortality is most pronounced in older 
populations, especially those over 65 years of age. However, 
in Poland nearly 40% of cancer deaths occur prematurely, 
i.e. before the age of 65. This stands in contrast to popula-
tions of other European countries, such as Sweden or the 
UK, where cancer deaths before the age of 65 average 20% 
and 25%, respectively [1].
Cancer is the second most common cause of death in 
Polish men and women. Moreover, lung cancer, a disease 
almost exclusively caused by tobacco smoke in developed 
populations, has historically ranked as the leading cause of 
cancer deaths in men, and since 2007, in women as well. This 
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manuscript aims to estimate tobacco-attributable cancer 
mortality in Poland. Knowing the magnitude of preventable 
cancer deaths will highlight arguments necessary for deci-
sion makers to adopt effective means of prevention, such 
as population wide smoking cessation support and other 
tobacco control measures. 
Material and methods
Data on cancer mortality for the period between 1994 
and 2014 come from the WHO Mortality Statistics databa-
se [2]. This source provided raw data in 5-year age groups, 
stratified by gender, on 10 cancer sites that have establi-
shed etiology to tobacco smoke [3], including: malignant 
neoplasm of trachea, bronchus and lung (ICD10: C33–C34), 
further denoted in this manuscript as lung cancer; malignant 
neoplasm of larynx (ICD10: C32), denoted as laryngeal can-
cer; malignant neoplasms of lip, oral cavity, and pharynx 
(ICD10: C00-C14), denoted as cancer of the oropharynx; 
malignant neoplasm of esophagus (ICD10: C15), denoted as 
esophageal cancer; malignant neoplasm of bladder (ICD10: 
C67), denoted as bladder cancer; malignant neoplasm of 
kidney, renal pelvis, ureter and other and unspecified urinary 
organs (ICD10: C64–C66, C68), denoted as kidney cancer; 
malignant neoplasm of pancreas (ICD10: C25), denoted as 
pancreatic cancer; malignant neoplasm of stomach (ICD10: 
C16), denoted as stomach cancer; lymphoid leukemia, my-
eloid leukemia, monocytic leukemia, other leukemias of 
specified cell types and unspecified cell types (ICD10: C91– 
–C95), denoted jointly as leukemia; malignant neoplasm 
of cervix uteri (ICD10: C53), denoted as cervical cancer. In 
addition to the 10 aforementioned cancer sites, we summed 
raw data from each cancer site to construct a combined 
category encompassing all tobacco-attributable cancers. 
Population data come from the Polish Central Statistical 
Office [4]. Data on smoking prevalence in Poland for years 
1974, 1982, 1985–1988, 1990–1994 come from standardi-
zed surveys based on nationally representative samples in 
subjects aged 15 years and over [5]. Relative risks, by gender, 
and separately for current and former smokers, come from 
the Cancer Prevention Study II [6]. The relative risk for those 
who have never smoked is equal to 1. 
The method applied in this manuscript assumes that 
there are no tobacco-attributed deaths before the age of 
35, as these occur extremely rarely [6], and for the sake of 
clarity they were set to zero in this model. The analysis was 
performed in four age groups: 35–44 years, 45–64 years, 
65 years and over (65+), and jointly for the entire analyzed 
population, aged 35 years and over (35+).
Tobacco-attributable fractions were calculated by gen-
der in 5-year age groups according to the following formula, 
which is standard methodology for calculating population-
-based attributable fractions [7–10].
TAF=
∑ Pi(Ri – 1)
∑ Pi(Ri – 1) + 1
k
k
i=1
i=1
Pi denotes smoking prevalence in a particular category 
of exposure (for never smokers i = 0) and RRi denotes relative 
risk for a particular category of exposure.
Application of the above formula returns a percentage 
of mortality that can be attributed to particular risk fac-
tors, such as tobacco smoking in this case. The returned 
percentage is used to obtain absolute numbers of smo-
king-attributable cancer deaths and for calculating age-
-standardized mortality rates attributed to smoking (rates 
were standardized to the world standard population). The 
model assumes a 20-year latency period between exposure 
to tobacco smoke and cancer death [6, 11].
For cancer sites not taken into account in this manu-
script, there is no sufficient evidence correlating their etio-
logy to tobacco smoke. While many studies describe an 
association between liver cancer, colorectal cancer, breast 
cancer, endometrial cancer, prostate cancer and tobacco 
smoke, the results remain inconclusive [3].
Results
Figure 1 presents trends in tobacco-attributable cancer 
mortality in Poland between the years 1994–2014 using 
three different measures: absolute number of deaths, age-
-standardized rates, and percentage of smoking-related 
cancer deaths among all analyzed cancer data. In men, the 
absolute number of tobacco-attributable cancer deaths 
remains relatively stable. In 2014, over 24 thousand of cancer 
deaths related to smoking were reported in men, constitu-
ting 75% of all cancer mortality1. Mortality rates experienced 
significant decline over the 20 years of observation from 
106.5/100,000 in 1994 to 77.2/100,000 in 2014. In women 
there has been observed increase in all three measures. In 
2014, there were over 7.5 thousand cancer deaths related 
to smoking in women, which constitutes 44% of all cancer 
mortality. Absolute numbers of tobacco-attributable cancer 
deaths more than doubled between 1994 (3678) and 2014 
(7652), and mortality rates rose from 12.6/100,000 in 1994 
to 19.6/100,000 in 2014. The fraction of tobacco-attributable 
cancers (of all types) also increased from 31% in 1994 to 
44%, 20 years later. 
Figure 2 presents time trends of tobacco-attributa-
ble cancer mortality rates compared to trends in cancers 
not attributed to tobacco use. In men, there is a wide gap 
between mortality rates attributed and not attributed to 
smoking. While tobacco-attributable cancer mortality rates 
1  Every time authors refer to „all cancer mortality”, that means all 10 cancer 
categories with established etiology to tobacco that were analyzed in this 
manuscript.
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declined for the 20-year period of observation, rates of mor-
tality in cancers not attributable to tobacco remained stable 
or decreased slightly. In 2014, death rates not attributed to 
tobacco were three times lower than those attributed to 
tobacco, at 25/100,000 and 77.2/100,000, respectively. In 
women the picture looks considerably different. While can-
cer mortality rates not attributed to tobacco are historically 
higher than those attributed to smoking, they converged 
in 2014. We observed an increase in tobacco-attributa-
ble cancer mortality rates from 12.6/100,000 in 1994 to 
19.6/100,000 in 2014. Overall cancer mortality rates not 
attributed to tobacco dropped from 25.8/100,000 in 1994 
to 20.8/100,000 in 2014.
Figure 3 presents a ranked list of tobacco-attributable 
fractions (TAF) of cancer mortality in Poland in 2014. In men, 
lung cancer tops this ranked list, with a tobacco-attributable 
fraction of 93%. Next are laryngeal (TAF = 90%), oropharyn-
geal (TAF = 86%) and esophageal (TAF = 80%) cancer, while 
the lowest tobacco-attributable fraction was observed in 
leukemia (TAF = 34%). When considered together, two-
-thirds of all cancer deaths are attributed to tobacco smoke 
(TAF = 75%). In women, laryngeal and lung cancer (both TAF 
= 76%) share the top position in the ranked list, followed 
by esophageal (TAF = 61%) and oropharyngeal (TAF = 51%) 
cancer. The lowest tobacco-attributable fractions were obse-
rved for kidney cancer (TAF = 7%) and leukemia (TAF = 5%), 
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Figure 1. Poland 1994–2014: Tobacco-attributable cancer mortality
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Figure 2. Poland 1994–2014: Cancer mortality rates attributed and not attributed to smoking
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and almost half of all considered cancer deaths were attri-
buted to tobacco smoke (TAF = 44%). 
Figure 4 presents a ranked list of tobacco-attributable 
age-standardized cancer mortality rates per 100,000 per-
son/year in Poland in 2014. In both men and women lung 
cancer mortality rates dominate the lists with 47.2/100,000 
in men, and 14.3/100,000 in women. The next highest rates 
are eight to nine times lower, with oropharyngeal cancer at 
5.9/100,000 in men, and pancreatic cancer at 1.6/100,000 
in women.
Additional material (Annex 1) includes 44 graphs with 
tobacco-attributable cancer mortality trends, over time, 
for the 10 cancer sites/groups analyzed, and for all cancers 
combined across four age groups. For males, there is a ge-
nerally observable pattern of decline in tobacco-attributable 
cancer mortality rates across all cancer sites/groups, with 
the exception of oropharyngeal cancer, where an increase 
is observed among middle-aged adults (45–64 years) and 
adults over the age of 65 years. For women, a general in-
crease or plateau in tobacco-attributable cancer mortality 
rates across all cancer sites/groups is observed, with the 
exception of the youngest age group (35–44 years) where 
we observed decreasing mortality rates.
Discussion
Tobacco smoking is one of the best documented risk 
factors for cancer in both men and women [12]. Since es-
tablishing the etiological association between exposure to 
tobacco smoke and mortality [13, 14], estimating the death 
toll of tobacco use has been plagued by controversies re-
garding limitations of quantitative methods, and results of 
such analyses constantly face criticism by various entities, 
including the tobacco industry [15].
One limitation of methods aiming to estimate tobacco-
-attributable mortality lies is defining smokers as current, 
former, and never smokers [12, 15, 16], which significantly 
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impacts downstream results [15, 17]. Defining smokers as 
a homogeneous group without accounting for the number 
of cigarettes smoked, age at which smoking began, length 
of exposure, and other variables that may impact risk, can 
lead to considerable differences in estimation results [15].
Newly emerging evidence, such as the recent finding of 
a causal relationship between tobacco smoking and breast 
cancer risk, must also be considered when analyzing tobac-
co-attributable cancer mortality rates [18, 19]. Although 
relative risk for breast cancer was not included in CPS-II, 
the most current and comprehensive set of relative risks 
for tobacco-attributable diseases, future data sets will likely 
include breast cancer, given the strength of the newest data.
As indicated by the results of this analysis, the greatest 
tobacco-attributable fractions of mortality rates are found in 
lung and laryngeal cancer, followed by cancer of oropharynx 
and esophagus. It should be noted that each of these sites 
is also etiologically related to alcohol consumption, and 
this method of analysis precludes separation of tobacco 
effects from effects of alcohol carcinogens. Moreover, the-
se two behaviors, tobacco smoking and alcohol drinking, 
often occur together, and alcohol can alter the chemical 
properties of tobacco smoke carcinogens, enabling them 
to more easily penetrate cells and damage DNA. Therefore, 
the risk of tobacco related cancer deaths is likely elevated 
when alcohol is consumed. 
In Poland, 75% of cancer deaths in men, and 44% in wo-
men, are caused by tobacco smoking. These figures translate 
to over 24 thousand men, and over 7.5 thousand women, 
who die prematurely due to tobacco use. This loss of human 
capital seems particularly immense given that it can be fully 
avoided by cessation of tobacco smoking. 
Reducing prevalence of tobacco smoking will limit both 
morbidity and mortality from cancer attributable to tobacco 
smoke, as well as many other chronic conditions that are 
related to smoking, such as chronic obstructive pulmonary 
disease and cardiovascular diseases, which are the leading 
cause of death in Poland. Data suggest that nearly half of 
daily smokers, who took up smoking early in life, will die 
prematurely due to tobacco-attributable diseases [12].
Despite enormous efforts of medical professionals and 
the research community, the treatment of cancer remains 
a significant clinical challenge. However, one certain way 
to reduce the risk of death from lung cancer and other to-
bacco-attributable cancers is strict avoidance of smoking or 
quitting before the age of 35. To achieve this, health compe-
tences must be improved among both general population 
and physicians. Moreover, giving up smoking at any stage 
of cancer remains the most effective secondary and tertiary 
prevention [20]. 
Taking up smoking should be unattractive, difficult and 
costly, whereas help in quitting smoking should be made 
broadly available, affordable, and provided by the natio-
nal health care system. Tailored interventions in tobacco 
control should be a priority of a country that loses tens of 
thousands of their citizens every year to the deadly habit 
of tobacco smoking. 
Conclusions
Tobacco smoking and tobacco-attributable cancer mor-
tality remains one of the most significant health burdens 
in the Polish population. Annually, more than 30 thousand 
Polish men and women die from cancer caused by smoking. 
All of these deaths are avoidable, though eliminating tobac-
co-associated cancer is not possible without eliminating 
tobacco use. Intensifying the Polish government’s efforts 
in tobacco control policy, especially improvement in tre-
atment of tobacco dependence syndrome and increasing 
expenditures on health interventions directed at reducing 
harm caused by tobacco, should be the main focus of health 
decision makers in years to come. 
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POLAND 1994-2014: Tobacco-  cancer mortality rates in age groups: 35-44, 45-64, 65+, 35+
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